Momentum: MACD histogram -0.957 and negatively expanding = bearish momentum still building, not yet stabilizing.
RSI (6): 31.18 (near oversold/low zone). This can support a short-term bounce, but it’s not a reversal signal by itself.
Key levels: Support S1 ~59.17 (price ~58.96 post-market is slightly below it); next support S2 ~55.67. Resistance/pivot: Pivot ~64.82, then R1 ~70.48.
Near-term pattern stats (similar candlesticks): modest positive drift expected (+1.84% 1-week, +5.55% 1-month), but this conflicts with the current bearish trend indicators—treat as lower-confidence without confirmation above ~64.8.
Options Data
Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio
Sentiment: Put/Call ratios are very low (OI PCR 0.56; Volume PCR 0.02) → positioning/flow skewed bullish via calls.
Volatility: IV30 ~84.75 vs HV ~60.07; IV percentile ~91.63 → options are priced rich (market expecting large moves).
Activity: Today’s option volume (288) is far below 5D/10D average (3335/3665), so the bullish skew is not backed by heavy volume today.
Setup implication: If trading, defined-risk structures tend to make more sense than outright long premium given elevated IV—especially with earnings approaching (2026-02-19 AH).
Technical Summary
Sell
10
Buy
2
Positive Catalysts
Earnings catalyst upcoming: QDEC 2025 earnings on 2026-02-19 (after hours). A solid guide could trigger a sharp rebound given depressed sentiment/levels.
Options market skew is call-favored (low put/call ratios), suggesting traders are leaning toward upside.
Regular session strength (+3.72%) hints at dip-buying interest near support (though post-market gave back some gains).
Neutral/Negative Catalysts
No supportive news flow in the last week; no fresh catalyst to justify chasing.
Financial Performance
Latest reported quarter: 2025/Q3.
Revenue: $617.143M, up +0.40% YoY (growth has essentially stalled).
Profitability: Net income -24.09% YoY to $33.102M; EPS -25.51% YoY to 0.73.
Margins: Gross margin 34.8%, down -3.76% YoY → profitability pressure is a clear negative trend.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Street stance has shifted more cautious: multiple Holds/Neutrals and lowered targets post-Q3.
Key recent actions:
Jefferies (2025-11-20): Downgrade to Hold; PT cut to $61 from $80 citing lagging organic growth and prolonged normalization.
UBS (2026-01-19): PT raised to $75 (from $70) but stays Neutral; notes 2026 outlook still soft and pipeline visibility low.
Truist (2026-01-06): Initiated Hold with $72; wants proof AI pods can re-accelerate growth while sustaining margins.
Needham (2025-11-14): Maintains Buy (PT to $80 from $85) on belief growth improves gradually in FY26 as AI projects scale.
Wall Street pros vs cons:
Pros: AI transition narrative + potential FY26 re-acceleration if AI work moves into production.
Cons: Soft 2026 visibility, weak recent growth/profit trends, and multiple firms signaling normalization will take time.
Wall Street analysts forecast GLOB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GLOB is 76.36 USD with a low forecast of 61 USD and a high forecast of 100 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
13 Analyst Rating
Wall Street analysts forecast GLOB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GLOB is 76.36 USD with a low forecast of 61 USD and a high forecast of 100 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
8 Hold
0 Sell
Moderate Buy
Current: 57.720
Low
61
Averages
76.36
High
100
Current: 57.720
Low
61
Averages
76.36
High
100
UBS
Neutral
maintain
$70 -> $75
AI Analysis
2026-01-19
Reason
UBS
Price Target
$70 -> $75
AI Analysis
2026-01-19
maintain
Neutral
Reason
UBS raised the firm's price target on Globant to $75 from $70 and keeps a Neutral rating on the shares. The firm expects the company to meet its guidance in Q4 but says its 2026 outlook is "still soft." Globant's visibility on pipeline conversion remains low, the analyst tells investors in a research note.
Truist
Hold
initiated
$72
2026-01-06
Reason
Truist
Price Target
$72
2026-01-06
initiated
Hold
Reason
Truist initiated coverage of Globant with a Hold rating and $72 price target. Globant is taking decisive steps to transition its business model as GenAI reshapes the industry and currently trades at trough multiples reflecting slowing revenue growth, the analyst tells investors in a research note. A more constructive view would emerge with evidence that its AI pods can drive growth re-acceleration while sustaining healthy margins and cash flow, Truist says.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for GLOB
